|
A high-tech product from green tea
yields increasing revenue Veregen®, used in the treatment of external genital warts, is MediGene’s first proprietary clinical development. Veregen® is
already available on the US, German, and Austrian markets. Several marketing partnership agreements have been concluded for other countries in Europe, Asia, and America, and will contribute
to future sales growth. An overview can be found here.
Veregen® makes MediGene the first German biotech company to have a drug on the US market.
Veregen® is an innovative drug based on an extract from green tea leaves obtained in a highly complex, predefined process.
Genital warts are skin tumors in the genital and anal areas that, while benign, are painful and disfiguring. This sexually transmitted disease is caused by a number of human
papillomaviruses (HPV). Genital warts are one of the fastest spreading venereal diseases worldwide.
Additional information:
MediGene’s marketing partnerships www.veregen.com
|
|
Outlook
The market approval for the drug granted in Germany, the reference member state in this decentralized procedure, will provide the basis for additional market approval procedures in
other 17 European countries within the mutual recognition procedure. MediGene intends to conclude additional marketing agreements for the commercialization of Veregen®
in further countries.
Changes in a skin tumor induced by Veregen® |
 
 |
 |
|
HPV infection of skin cells induces formation of warts |
 |
|
Veregen® penetrates the skin, unfolds its immuno-modulatory effect and also directly acts on infected cells |
 |
|
Messengers (Cytokines, Interferones) are releasedt |
 |
|
Cells of the immune system invade and destroy infected cells
Veregen® is the brandname of the drug. The European marketing authorization application is made out to the name of Polyphenon E®
Ointment. |
| |
|
Veregen® is a trademark of MediGene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. |
|
|
